Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Chronic Myeloproliferative disorders

On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia

Abstract

Lonafarnib is an orally bio-available farnesyltransferase inhibitor that prevents farnesylation of specific target proteins including Ras. In a multicenter study, 67 patients with advanced myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) were treated with a continuous oral dose of 200–300 mg of lonafarnib and were evaluated for hematologic, pathologic and pharmacodynamic response. The median age of patients was 70 years (range 44–86). There were 32 patients with MDS (RAEB-20 and RAEB-t-12) and 35 with CMML. Overall 16 (24%) of the patients responded with two patients achieving a complete remission and one a partial response. Responses were seen in 6/32 and 10/35 patients with MDS and CMML, respectively. Of the 19 patients who were platelet transfusion-dependent prior to treatment, 5 (26%) became transfusion-free for a median duration of 185 days. A decrease in the farnesylation of the HDJ-2 protein measured in patient-derived cells was observed in the majority of patients during treatment with lonafarnib, but no clear correlation between changes in farnesylation and clinical effect could be made. Gastrointestinal toxicity was significant with 19% of patients discontinuing therapy due to diarrhea, nausea and/or anorexia. Lonafarnib has demonstrable activity in patients with advanced MDS and CMML.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Hofmann WK, Koeffler HP . Myelodysplastic syndrome. Annu Rev Med 2005; 56: 1–16.

    Article  CAS  Google Scholar 

  2. Blinder VS, Roboz GJ . Hematopoietic growth factors in myelodysplastic syndromes. Curr Hematol Rep 2003; 2: 453–458.

    PubMed  Google Scholar 

  3. List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D et al. Efficacy of lenalidomide in myelodysplastic syndromes. NEJM 2005; 352: 549–557.

    Article  CAS  Google Scholar 

  4. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimer-Reissig R et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002; 20: 2429–2440.

    Article  CAS  Google Scholar 

  5. Rosenfeld C, List A . A hypothesis for the pathogenesis of myelodysplastic syndromes: implications for new therapies. Leukemia 2000; 14: 2–8.

    Article  CAS  Google Scholar 

  6. Clark GJ, Der CJ . Ras proto-oncogene activation in human malignancy. In Garrett CT, Sell S (eds). Cellular Cancer Markers, Vol. 1 Humana Press: Totowa, NJ, 1995, pp 17–52.

    Chapter  Google Scholar 

  7. Paquette RL, Landaw EM, Pierre RV, Kahan J, Lubbert M, Lazcano O . N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome. Blood 1993; 82: 590–599.

    CAS  PubMed  Google Scholar 

  8. Cogswell PC, Morgan R, Dunn M, Neubauer A, Nelson P, Poland-Johnston NK et al. Mutations of the ras protooncogenes in chronic myelogenous leukemia: a high frequency of ras mutations in bcr/abl rearrangement-negative chronic myelogenous leukemia. Blood 1989; 74: 2629–2633.

    CAS  PubMed  Google Scholar 

  9. Lu D, Nounou R, Beran M, Estey E, Manshouri T, Kantarjian H et al. The prognostic significance of bone marrow levels of neurofibromatosis-1 protein and ras oncogene mutations in patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer 2003; 97: 441–449.

    Article  CAS  Google Scholar 

  10. Rowell CA, Kowalczyk JJ, Lewis MD, Garcia AM . Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo. Biol Chem 1997; 272: 14093–14097.

    Article  CAS  Google Scholar 

  11. Ganguly AK, Doll RJ, Girijavallabhan VM . Farnesyl protein transferase inhibition: a novel approach to anti-tumor therapy. The discovery and development of SCH 66336. Curr Med Chem 2001; 8: 1419–1436.

    Article  CAS  Google Scholar 

  12. Lebowitz PF, Prendergast GC . Non-Ras targets of farnesyltransferase inhibitors: focus on Rho. Oncogene 1998; 17 (11 Reviews): 1439–1445.

    Article  CAS  Google Scholar 

  13. Karp JE, Lancet JE, Kaufmann SH, End DW, Wright JJ, Bol K et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood 2001; 97: 3361–3369.

    Article  CAS  Google Scholar 

  14. Eskens FA, Awada A, Cutler DL, de Jonge MJ, Luyten GP, Faber MN et al. Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors. J Clin Oncol 2001; 19: 1167–1175.

    Article  CAS  Google Scholar 

  15. Khuri FR, Glisson BS, Kim ES, Statkevich P, Thall PF, Meyers ML et al. Phase I study of the farnesly transferase inhibitor lonafarnib with paclitaxel in solid tumors. Clin Cancer Res 2004; 10: 2968–2976.

    Article  CAS  Google Scholar 

  16. List A, DeAngelo S, O’Brien S, Cortes J, Wilson J, Sugrue M et al. Phase I study of continuous oral lonafarnib in patients with advanced hematologic malignancies. Blood Suppl Dec 2002; 102(11); abstract 3120.

  17. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000; 96: 3671–3674.

    CAS  Google Scholar 

  18. Britten CD, Rowinsky E, Soignet S, Patnaik A, Yao SL, Deutsch P et al. A Phase I and Pharmacological Study of the Farnesyl Protein Transferase Inhibitor L-778, 123 in Patients with Solid Malignancies. Clin Cancer Res 2001; 7: 3894–3903.

    CAS  PubMed  Google Scholar 

  19. Karp JE, Lancet JE . Development of the farnesyltransferase inhibitor tipifarnib for therapy of hematologic malignancies. Future Oncol 2005; 1: 719–731.

    Article  CAS  Google Scholar 

  20. Kurzrock R, Kantarjian HM, Cortes JE, Singhania N, Thomas DA, Wilson EF et al. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. Blood 2003; 102: 4527–4534. epub 2003 Aug 28.

    Article  CAS  Google Scholar 

  21. Kurzrock R, Albitar M, Cortes JE, Estey EH, Faderl SH, Garcia-Manero G et al. Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J Clin Oncol 2004; 22: 1287–1292.

    Article  CAS  Google Scholar 

  22. Fenaux P, Raza A, Mufti GJ, Aul C, Germing U, Kantarjian H et al. A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate to high-risk myelodysplastic syndrome. Blood 2007; 109: 4158–4163.

    Article  CAS  Google Scholar 

  23. Kurzrock R, Kantarjian H, Blascovich MA, Bucher C, Verstovesek S, Wright J et al. Phase I study using alternative week administration of the farnesyltransferase inhibitor R115777 (Zarnestra™) in patients with myelodysplastic syndrome. Clin Cancer Res 2008; 14: 509–514.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to E J Feldman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Feldman, E., Cortes, J., DeAngelo, D. et al. On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia. Leukemia 22, 1707–1711 (2008). https://doi.org/10.1038/leu.2008.156

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2008.156

Keywords

This article is cited by

Search

Quick links